The global Glycomics Glycobiology Market reached a valuation of USD 2.26 Billion in 2022, and it is anticipated to maintain a robust growth trajectory, projecting a substantial compound annual growth rate (CAGR) of 13% throughout the forecast period. This impressive expansion can be attributed to a confluence of key factors propelling the market's revenue augmentation. Among these factors, the escalating prevalence of chronic diseases, a surge in Research Development (RD) investments within the glycomics domain, and the growing demand for personalized medical treatments stand as pivotal drivers of this upward revenue trajectory.
Glycomics, also referred to as glycobiology, constitutes the scientific exploration of saccharides, commonly known as glycans, which are ubiquitously distributed across nature. The focus of this field spans the structural, biological, and functional aspects of these glycans. The applications of glycomics are far-reaching and encompass domains such as diagnostics, oncology, drug discovery, immunology, and various other biomedical fields.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/3986
An essential catalyst driving the market's expansion is the rising prevalence of chronic ailments like cancer, diabetes, and cardiovascular diseases. This burgeoning incidence has intensified the scrutiny of carbohydrates and their roles in disease initiation and progression. Of particular significance are complex carbohydrates, termed glycans, which play critical roles in numerous biological processes such as protein folding, immune system modulation, and cell signaling. The profound understanding of these glycan-related mechanisms has the potential to unlock novel therapeutic targets and foster the development of customized treatments tailored to individual patient needs.
The commitment to advancing glycomics research is evident in the substantial surge in RD expenditures within the sector. The pharmaceutical and biotech sectors have channeled significant investments into glycomics RD endeavors, with the aim of innovating new medications and treatments.
In examining the market landscape, key takeaways emerge concerning various aspects of glycomics and glycobiology:
Product Type Outlook: The market's segmentation by product type encompasses enzymes, instruments, kits, reagents, and other categories. Notably, the enzymes segment claimed the largest revenue share in 2022, driven by their escalating utilization in biotechnology and pharmaceutical applications. Enzymes assume a pivotal role in carbohydrate structure analysis, rendering them indispensable tools for glycomics research.
Steering the market towards a promising trajectory, the instruments segment is anticipated to record steadfast revenue growth. This projection can be attributed to the escalating adoption of technologies like High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Capillary Electrophoresis (CE) for glycomics research. Additionally, the development of novel tools such as lectin microarrays and glycan microarrays is poised to stimulate revenue generation within this segment.
Meanwhile, the kits segment is projected to command a significantly large share of the market's revenue. This prominence arises from the increasing availability of affordable and user-friendly glycan analysis kits. The kits find applications in diverse scientific disciplines, spanning immunology, microbiology, and oncology, thereby contributing to the segment's revenue growth.
End-use Outlook: The market's end-use segmentation encompasses Contract Research Organizations (CROs), biotechnology and pharmaceutical companies, academic and research institutions, and others. In this context, academic and research institutes are poised to achieve the fastest revenue growth during the forecast period. The impetus behind this surge stems from a heightened emphasis on glycomics research activities, aided by governmental financial support. Furthermore, the proliferating collaborations between academic institutions and biotech/pharmaceutical firms are forecasted to fuel revenue expansion within this segment.
Simultaneously, CROs are anticipated to seize a substantial revenue share, driven by the escalating demand for cost-effective and efficient drug discovery and development processes. Biotech and pharmaceutical companies are increasingly outsourcing research activities to CROs, thereby propelling the revenue growth in this segment.
Regional Outlook: Geographically, North America emerged as the dominant revenue contributor in 2022. This supremacy can be attributed to well-established pharmaceutical and biotech industries, substantial RD investments, and the growing awareness of personalized medicine. Furthermore, the region's elevated prevalence of chronic ailments, including diabetes and cancer, is anticipated to fortify market growth.
The European market is poised to achieve moderate revenue growth during the forecast period. This projection is underpinned by increasing RD investments and the prevalence of chronic diseases. Additionally, the role of glycomics and glycobiology in food processing, preservation, and flavoring within the Food Beverage (FB) sector is expected to stimulate revenue generation.
Within the Asia Pacific region, a substantial revenue share is foreseen. The region's heightened investments in RD activities, coupled with growing awareness of personalized medicine, contribute to this forecast. Moreover, the region's sizable population and the rising incidence of chronic ailments underscore the potential for robust revenue growth.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/3986
Competitive Landscape: Prominent companies shaping the global glycomics/glycobiology market landscape include Agilent Technologies, Bruker Corporation, Danaher Corporation, New England Biolabs, Shimadzu Corporation, Thermo Fisher Scientific, Waters Corporation, and Zymo Research Corporation. These entities are engaged in strategic endeavors that contribute to their market positioning.
Agilent Technologies, for instance, acquired Resolution Bioscience in March 2021, with the aim of enhancing its molecular diagnostics offerings, particularly in the domain of liquid biopsy-based cancer detection. Similarly, Danaher Corporation's acquisition of GE Biopharma in March 2020 bolstered its bioprocessing market presence. This strategic move was driven by a desire to augment the production of biotherapeutics.
Segments Covered in the Report: The comprehensive market report delves into historical data and future projections at the global, regional, and country levels. It delves into trends and analyses within segments and sub-segments spanning the period from 2019 to 2032. The segmentation encompasses product types, applications, end-use categories, and regions.
Product Type Outlook (Revenue, USD Billion; 2019-2032):
- Enzymes
- Instruments
- Kits
- Reagents
- Others
Application Outlook (Revenue, USD Billion; 2019-2032):
- Drug discovery and development
- Diagnostic applications
- Oncology
- Immunology
- Others
End-use Outlook (Revenue, USD Billion; 2019-2032):
- Academic and research institutes
- Biotechnology and pharmaceutical companies
- Contract Research Organizations (CROs)
- Others
Regional Outlook (Revenue, USD Billion; 2019-2032):
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/3986
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Varicose Vein Treatment Devices Market
Cannabidiol (CBD) Gummies Market
Myopia Presbyopia Treatment Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
